GlassScriptPhysician profile
Kelley Denise Walker
NPI 1730173790
$17,064.45
in general payments reported to CMS, 2019-2025
37 companies · $2,290 in 2025
The $2,290 reported for 2025 was more than what 90% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,619 · 2020: $1,994 · 2021: $2,654 · 2022: $2,476 · 2023: $2,673 · 2024: $2,360 · 2025: $2,290.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,323.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,322.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $1,877.62 | 2019-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $1,781.01 | 2019-2025 | Rexulti, Abilify Asimtufii, Nuedexta |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,360.37 | 2020-2025 | Caplyta |
| Alkermes, INC. | $1,241.20 | 2019-2025 | Aristada, Lybalvi, Aristada Initio |
| Teva Pharmaceuticals USA, INC. | $1,182.98 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Janssen Pharmaceuticals, INC | $1,102.14 | 2019-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Sunovion Pharmaceuticals INC. | $887.94 | 2019-2022 | |
| Abbvie INC. | $870.90 | 2021-2025 | Vraylar |
| Ironshore Pharmaceuticals INC. | $763.46 | 2019-2024 | Jornay Pm |
| Axsome Therapeutics, INC. | $644.46 | 2023-2025 | Auvelity, Sunosi |
| Allergan, INC. | $632.19 | 2019-2020 | |
| Lundbeck LLC | $544.56 | 2019-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $519.13 | 2019-2025 | Fanapt, Hetlioz |
| Corium, LLC | $511.85 | 2022-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $471.20 | 2021-2023 | Qelbree |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $348.45 | 2019-2025 | Dyanavel Xr |
| Jazz Pharmaceuticals INC. | $329.41 | 2019-2022 | |
| Adlon Therapeutics L.P. | $248.26 | 2019-2021 | |
| Harmony Biosciences LLC | $245.13 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $207.69 | 2020-2025 | Trintellix |
| Neos Therapeutics, LP | $200.89 | 2019-2024 | Adzenys Xr-Odt |
| E.R. Squibb & Sons, L.L.C. | $184.26 | 2024-2025 | Cobenfy |
| Eisai INC. | $125.47 | 2020-2021 | |
| Idorsia Pharmaceuticals US INC | $116.89 | 2022-2024 | Quviviq |
| Bausch Health US, LLC | $88.85 | 2020-2023 | Aplenzin, Wellbutrin |
| Noven Therapeutics, LLC | $84.10 | 2024-2025 | Secuado, Xelstrym |
| Merck Sharp & Dohme LLC | $82.92 | 2022-2023 | Belsomra |
| Almatica Pharma LLC | $80.88 | 2022-2023 | Loreev Xr, Sertraline Hcl |
| Shire North American Group INC | $77.88 | 2019 | |
| Avanir Pharmaceuticals, INC. | $48.72 | 2019-2021 | |
| Mdd US Operations, LLC | $47.04 | 2019 | |
| Collegium Pharmaceutical, INC. | $43.04 | 2025 | Jornay Pm |
| Braeburn INC. | $39.30 | 2024 | Brixadi |
| Indivior INC. | $22.40 | 2022 | |
| Alfasigma USA, INC. | $21.40 | 2020 | |
| Aytu Biopharma, INC. | $15.29 | 2019 | |
| Rhodes Pharmaceuticals L.P. | $15.17 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelley Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.